Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

Jun 24 2022

• By Brenda Sandburg

Respiratory syncytial virus — CDC advisory committee plans to review five RSV vaccines in the next year • Source: Shutterstock

Related Content

US FDA Ups The Stakes In RSV Vaccine Race With Breakthrough Designations For Pfizer And Bavarian Nordic

Mar 15 2022

GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial

Jun 10 2022

Beyond Vaccines: CDC's ACIP To Look At Antibodies For Respiratory Syncytial Virus Prevention

Jan 24 2022

GSK Halts Enrollment In Maternal RSV Vaccine Trials As Setback Intensifies

Feb 28 2022

Pfizer Doubles Down In RSV By Buying ReViral

Apr 07 2022

Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge

Mar 03 2022

Related Companies

Janssen Pharmaceuticals Inc.

Moderna, Inc.

Bavarian Nordic A/S

Swedish Orphan Biovitrum AB

Sanofi Pasteur

GSK plc

ReViral Ltd.

Additional Topics

United States Advisory Committees Vaccines Clinical Trials Research & Development Pediatrics Policy Infectious Diseases BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window